Jonathan Young Sells 2,503 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 2,503 shares of Akero Therapeutics stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total transaction of $77,067.37. Following the completion of the sale, the chief operating officer now directly owns 203,783 shares in the company, valued at approximately $6,274,478.57. The trade was a 1.21 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Jonathan Young also recently made the following trade(s):

• On Monday, December 2nd, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $32.13, for a total transaction of $321,300.00.
• On Friday, November 1st, Jonathan Young sold 50,716 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.57, for a total transaction of $1,601,104.12.
• On Monday, October 14th, Jonathan Young sold 40,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $30.15, for a total transaction of $1,206,000.00.
• On Tuesday, October 1st, Jonathan Young sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $28.18, for a total transaction of $281,800.00.

Akero Therapeutics Stock Down 0.5 %

Shares of NASDAQ AKRO opened at $28.89 on Friday. Akero Therapeutics, Inc. has a 12-month low of $15.32 and a 12-month high of $37.00. The company has a market capitalization of $2.02 billion, a PE ratio of -7.70 and a beta of -0.23. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm’s 50-day moving average is $30.81 and its two-hundred day moving average is $27.08.

Akero Therapeutics (NASDAQ:AKRO) last announced its quarterly earnings results on Friday, November 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.15). Equities analysts anticipate that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Analysts Set New Price Targets

AKRO has been the topic of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup initiated coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They set a “buy” rating and a $65.00 price objective on the stock. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.83.

Institutional Trading of Akero Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Exome Asset Management LLC purchased a new stake in shares of Akero Therapeutics in the third quarter valued at about $2,212,000. Barclays PLC lifted its holdings in shares of Akero Therapeutics by 127.9% in the third quarter. Barclays PLC now owns 127,668 shares of the company’s stock valued at $3,662,000 after purchasing an additional 71,652 shares in the last quarter. Y Intercept Hong Kong Ltd lifted its stake in shares of Akero Therapeutics by 13.8% during the third quarter. Y Intercept Hong Kong Ltd now owns 16,916 shares of the company’s stock valued at $485,000 after buying an additional 2,049 shares during the period. XTX Topco Ltd purchased a new position in shares of Akero Therapeutics during the third quarter valued at approximately $308,000. Finally, Wellington Management Group LLP lifted its stake in shares of Akero Therapeutics by 54.4% during the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after buying an additional 2,782,029 shares during the period.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.